by Jeffrey Dach MD – Natural Solutions with Bio Identical Hormones
In part one of this series, we discussed a novel drug treatment called LDN (low dose naltrexone), useful in treatment of Multiple Sclerosis, inflammatory bowel disease and a variety of auto-immune diseases. In part two, this article takes an in-depth look at LDN as a treatment for cancer. In addition, we review an LDN book, The Promise of Low Dose Naltrexone Therapy by Elaine Moore and Samantha Wilkinson.
No doubt, future medical history books will look back and comment that the greatest medical discovery of the 20th century was the discovery of the opiate receptor system in the brain, and endogenous opioids called endorphins. Playing a key role in this discovery is the beneficial effect of Low Dose Naltrexone, an opiate blocker which can produce a rebound-like increase in endorphin production.
This largely ignored and inexpensive off-patent drug called LDN has been used with great success over the past 20 years by various renegade physicians to cure or induce remissions in a host of seemingly unrelated diseases such as Multiple Sclerosis, Crohn’s, Systemic Lupus, Rheumatoid Arthritis, Pancreatic Cancer and Lymphoma. LDN has also been found useful in Autism, and halts progression to opportunistic infection in AIDS patients.
Paradoxically, LDN’s ability to benefit so many seemingly unrelated medical conditions has been the greatest criticism from conventional mainstream medicine. If it sounds too good to be true, it probably is. However, since LDN is an FDA approved drug, off label use is perfectly legal, and is a common practice in mainstream medicine. LDN has virtually no adverse side effects, and based on my own short clinical experience prescribing LDN for Multiple Sclerosis, Crohn’s and Ulcerative Colitis, I can report that it is amazingly effective. Even though it may sound too good to be true, in the case of LDN, I can assure you that, yes, it is all true.
CLICK ON THE Low Dose Naltrexone LDN (Part 2) link above to read the rest of this article.
The Definitive Book on LDN
I (Jeffrey Dach MD) recommend for you a book on LDN, “The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders, by Elaine Moore and SammyJo Wilkinson. (1) The drug, Naltrexone, was developed in the 1960’s as part of the government’s War on Drugs, as a narcotics blocker intended as a treatment for narcotics addiction. However, narcotics addicts avoided it because of the narcotics withdrawal induced by the drug. However, over the years, Naltrexone found a niche for treatment and prevention of alcoholism. The usual tablet dosage is 50 mg, although some practitioners use a monthly injection for alcoholics. The book covers the use in LDN in the following disease categories (1):
|Low Dose Naltrexone Use in Disease Categories(1)|
As of this date, this is the first and only book of its kind on LDN, and as such represents a milestone in the effort to bring LDN into mainstream use. Written by Elaine Moore, a high level science writer with a portfolio of previous accomplishments, her LDN book is perhaps somewhat technical and may be difficult for the untrained non-professional to follow. It delves into the sophisticated jargon of the medical research world. However, in addition to the esoteric technical sections of the book, there are also chapters devoted to the lay reader interested in learning how LDN can help them on a practical level. A listing of dispensing practitioners was included. The book is highly recommended for other health care practitioners who wish to get quickly up to speed in this new area of medicine which is destined to become the medical paradigm of the 21st century, casting a giant shadow over the rest of mainstream medicine.